Tafinlar® (dabrafenib) and Mekinist® (trametinib) – New indication
June 22, 2017 – The FDA announced the approval of Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
Top